Matches in Wikidata for { <http://www.wikidata.org/entity/Q86245187> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q86245187 description "clinical trial" @default.
- Q86245187 description "ensayu clínicu" @default.
- Q86245187 description "klinisch onderzoek" @default.
- Q86245187 description "клінічне випробування" @default.
- Q86245187 name "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 name "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 type Item @default.
- Q86245187 label "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 label "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 prefLabel "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 prefLabel "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (2006-04-30)" @default.
- Q86245187 P1050 Q86245187-9A4C1720-6DB7-47F1-BA48-2D4BEAC72C2B @default.
- Q86245187 P1132 Q86245187-C47F6589-4E1E-4E2D-9A2C-2A6B48D9C333 @default.
- Q86245187 P1476 Q86245187-E817B7FD-5F01-45EA-AB80-3C0E288CF163 @default.
- Q86245187 P17 Q86245187-9EB67904-05E1-44C7-BF98-CCD68D2328C8 @default.
- Q86245187 P2899 Q86245187-154BA746-EA94-4AF7-83CF-D1B6DF3A06E5 @default.
- Q86245187 P3098 Q86245187-84414E19-6B60-4499-AFC9-5D37C4652440 @default.
- Q86245187 P31 Q86245187-A4A732ED-5FC1-4E85-BF43-7B776A9E5756 @default.
- Q86245187 P4844 Q86245187-1241051F-5368-4E1A-A261-D33399F7A301 @default.
- Q86245187 P4844 Q86245187-2F52ACA9-2E52-4511-9A43-64B1B33CFD05 @default.
- Q86245187 P4844 Q86245187-E16725DF-54F6-43DB-8D46-E3E20779438F @default.
- Q86245187 P580 Q86245187-1F96B2A7-005F-409E-9435-E884D0ECEF99 @default.
- Q86245187 P582 Q86245187-26DAA3AC-13CB-446B-9DBD-9A8AC87E7C13 @default.
- Q86245187 P6099 Q86245187-CDFDE886-2CB6-456C-8207-9CA8EEF7828C @default.
- Q86245187 P8363 Q86245187-CFF75C17-5AB6-414A-9103-183EB58A757A @default.
- Q86245187 P859 Q86245187-F2AAA1E7-4659-409E-B354-0DCA4A1DF28F @default.
- Q86245187 P1050 Q180614 @default.
- Q86245187 P1132 "+69" @default.
- Q86245187 P1476 "Phase 1 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma" @default.
- Q86245187 P17 Q30 @default.
- Q86245187 P2899 "+18" @default.
- Q86245187 P3098 "NCT00349206" @default.
- Q86245187 P31 Q30612 @default.
- Q86245187 P4844 Q32089 @default.
- Q86245187 P4844 Q421052 @default.
- Q86245187 P4844 Q421136 @default.
- Q86245187 P580 "2006-04-01T00:00:00Z" @default.
- Q86245187 P582 "2012-02-01T00:00:00Z" @default.
- Q86245187 P6099 Q5452194 @default.
- Q86245187 P8363 Q78089383 @default.
- Q86245187 P859 Q664846 @default.